Medibio Limited

Symbol: MEB.AX




Market price today

  • 0.0000

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 4.55M

    MRK Cap

  • 0.00%

    DIV Yield

Medibio Limited (MEB-AX) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Medical - Healthcare Information Services
CEO:Dr. Thomas R. Young M.D.
Full-time employees:4
Address:100 Albert Road

Medibio Limited, a health technology company, assists in the detection and screening of mental health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was incorporated in 1987 and is headquartered in Melbourne, Australia.

General Outlook

When we look at how much money they make before expenses, they keep 0.993% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -81.016%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -141.329%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.387% return, is a testament to Medibio Limited's adeptness in optimizing resource deployment. Medibio Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.466%. Furthermore, the proficiency of Medibio Limited in capital utilization is underscored by a remarkable -0.284% return on capital employed.

Stock Prices

Medibio Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.02, while its low point bottomed out at $0.02. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Medibio Limited's stock market.

Liquidity Ratios

Analyzing MEB.AX liquidity ratios reveals its financial health of the firm. The current ratio of 17.30% gauges short-term asset coverage for liabilities. The quick ratio (12.17%) assesses immediate liquidity, while the cash ratio (12.17%) indicates cash reserves.

Current Ratio17.30%
Quick Ratio12.17%
Cash Ratio12.17%

Profitability Ratios

MEB.AX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -14132.93% underscores its earnings before tax deductions. The effective tax rate stands at -30.61%, revealing its tax efficiency. The net income per EBT, 100.00%, and the EBT per EBIT, 174.45%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -8101.56%, we grasp its operational profitability.

Pretax Profit Margin-14132.93%
Effective Tax Rate-30.61%
Net Income per EBT100.00%
EBT per EBIT174.45%
EBIT per Revenue-8101.56%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.17, it details the span from stock purchase to revenue.

Days of Sales Outstanding12
Days of Payables Outstanding3191525
Cash Conversion Cycle-3191525
Fixed Asset Turnover0.21

Cash Flow Ratios

Lastly, the operating cash flow sales ratio, -42.23, offers insight into cash flow relative to sales.

Operating Cash Flow Sales Ratio-42.23
Free Cash Flow to Operating Cash Flow Ratio3.42
Cash Flow Coverage Ratio-8.99
Short Term Coverage Ratio-8.99
Capital Expenditure Coverage Ratio-0.41
Dividend Paid and Capex Coverage Ratio-0.41

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 1.29%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.02, we discern the balance between debt and equity financing. An interest coverage of -134.87 indicates its ability to manage interest expenses.

Debt Ratio1.29%
Debt Equity Ratio0.02
Total Debt to Capitalization1.62%
Interest Coverage-134.87
Cash Flow to Debt Ratio-8.99
Company Equity Multiplier1.28

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -44.87%, indicates top-line expansion, while the gross profit growth, -43.76%, reveals profitability trends. EBIT growth, 50.85%, and operating income growth, 50.85%, offer insights into operational profitability progression. The net income growth, 75.47%, showcases bottom-line expansion, and the EPS growth, 100.00%, measures the growth in earnings per share.

Revenue Growth-44.87%
Gross Profit Growth-43.76%
EBIT Growth50.85%
Operating Income Growth50.85%
Net Income Growth75.47%
EPS Growth100.00%
EPS Diluted Growth100.00%
Weighted Average Shares Growth-100.00%
Weighted Average Shares Diluted Growth-100.00%
Operating Cash Flow Growth43.88%
Free Cash Flow Growth33.11%
10-Year Revenue Growth per Share-100.00%
5-Year Revenue Growth per Share-100.00%
3-Year Revenue Growth per Share-100.00%
10-Year Operating CF Growth per Share100.00%
3-Year Operating CF Growth per Share100.00%
10-Year Net Income Growth per Share100.00%
5-Year Net Income Growth per Share100.00%
3-Year Net Income Growth per Share100.00%
10-Year Shareholders Equity Growth per Share-100.00%
5-Year Shareholders Equity Growth per Share-100.00%
3-Year Shareholders Equity Growth per Share-100.00%
Asset Growth-5.09%
Book Value per Share Growth-100.00%
Debt Growth56.13%
R&D Expense Growth-61.74%
SGA Expenses Growth-41.82%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, -110,410, captures the company's total value, considering both debt and equity. The sales, general, and administrative to revenue ratio, 34.15, gauges operational efficiency, while the research and development to revenue, 1391.45%, highlights investment in innovation. The ratio of intangibles to total assets, 94.70%, indicates the value of non-physical assets, and capex to operating cash flow, 242.33%, measures reinvestment capability.

Enterprise Value-110,410
Sales General and Administrative to Revenue34.15
Research and Development to Revenue1391.45%
Intangibles to Total Assets94.70%
Capex to Operating Cash Flow242.33%
Capex to Revenue-10232.27%
Return on Tangible Assets-730.42%
Working Capital-1,455,072
Tangible Asset Value-1,332,424
Net Current Asset Value-1,455,072
Average Payables1,191,404.5
Days Payables Outstanding3191525

Valuation Ratios

The price to sales ratio, 206.03, provides a perspective on valuation in relation to sales.

Price to Sales Ratio206.03
Enterprise Value Multiple-3.73
Price to Free Cash Flows Ratio-1.43
Enterprise Value to Sales-5.00
Enterprise Value Over EBITDA0.09
EV to Operating Cash Flow0.12
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Medibio Limited (MEB.AX) on the ASX in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 0.000 in 2024.

What is the ticker symbol of Medibio Limited stock?

The ticker symbol of Medibio Limited stock is MEB.AX.

What is company IPO date?

IPO date of Medibio Limited is 2001-01-28.

What is company current share price?

Current share price is 0.001 AUD.

What is stock market cap today?

The market cap of stock today is 4547930.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 4.